MSMarie J. Stuart

Marie J. Stuart

*This is an algorithmically generated author record based on publicly available information.

Marie J. Stuart has a total of 10 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Acute chest syndrome of sickle cell disease: new light on an old problem

    by Marie J. Stuart, B.N. Yamaja Setty

    The pulmonary findings of acute chest syndrome of sickle cell disease have been well characterized in numerous studies. Whereas a third of patients have a documented infection associated with this syndrome, and fat embolism from necrotic marrow is the etiologic factor in another approximately 10%, no cause is discovered in the majority of patients. In most patients, however, the underlying pathophysiology is the presence of a hypoxia-driven, adhesion-related occlusive event in the pulmonary microcirculation. This may be accompanied by a decrease in the levels of normal cytoprotective and anti-adhesive mediators such as nitric oxide. In the patient with sickle cell disease, the lung is also a uniquely vulnerable target organ because its vasculature constricts with hypoxia in contrast to other vascular beds. This review will establish the links between known etiologic agents and the pathophysiology of this syndrome. An additional section of this review will deal with experimental therapies. The use of inhaled nitric oxide will be explored in depth because advances in this area are current and uniquely relevant to acute chest syndrome.


    • 1 August 2000
      • Vol. 96  (3) , 1119-24

    Fetal hemoglobin in sickle cell disease: relationship to erythrocyte phosphatidylserine exposure and coagulation activation.

    by B N Setty, S Kulkarni, A K Rao, M J Stuart

    In sickle cell disease (SCD), loss of erythrocyte membrane phospholipid asymmetry occurs with the exposure of phosphatidylserine (PS), which provides a docking site for coagulation proteins. In vivo sickling/desickling, with resulting red cell membrane changes and microvesicle formation, appears to be one of the factors responsible for PS exposure. We evaluated children with SCD homozygous for sickle hemoglobin (SS disease) and controls (n = 65) and demonstrate that high levels of fetal hemoglobin (assessed as F cells) are associated with decreased microvesicle formation, PS exposure, and thrombin generation. F cells correlated inversely with both microvesicles and PS positivity (P <.000001) in SS disease. Multiple regression analyses using various hematologic parameters as independent variables, and either microvesicles or PS positivity as the dependent variable, showed a strong relationship only with F cells. Additionally, plasma prothrombin fragment F1.2 levels (a marker for thrombin generation) correlated with both PS positivity (P <.001) and F cells (P <.01). An F-cell level of approximately 70% was associated with normal levels of prothrombin fragment F1.2 and with microvesicle formation indistinguishable from control values. We suggest that the use of such surrogate biologic markers in conjunction with F-cell numbers may provide valuable insights into the biology and consequences of in vivo sickling.


    • 1 September 1999
      • Vol. 94  (5) , 1555-60

    Sickle cell acute chest syndrome: pathogenesis and rationale for treatment.

    by M J Stuart, B N Setty

    Acute chest syndrome (ACS) is a leading cause of death in sickle cell disease (SCD). Our previous work showed that hypoxia enhances the ability of sickle erythrocytes to adhere to human microvessel endothelium via interaction between very late activation antigen-4 (VLA4) expressed on sickle erythrocytes and the endothelial adhesion molecule vascular cell adhesion molecule-1 (VCAM-1). Additionally, hypoxia has been shown to decrease the production of nitric oxide (NO) which inhibits VCAM-1 upregulation. Based on these observations, we hypothesize that during ACS, the rapidly progressive clinical course that can occur is caused by initial hypoxia-induced pulmonary endothelial VCAM-1 upregulation that is not counterbalanced by production of cytoprotective mediators, including NO, resulting in intrapulmonary adhesion. We assessed plasma NO metabolites and soluble VCAM-1 in 36 patients with SCD and 23 age-matched controls. Patients with SCD were evaluated at baseline (n = 36), in vaso-occlusive crisis (VOC; n = 12), and during ACS (n = 7). We observed marked upregulation of VCAM-1 during ACS (1,290 +/- 451 ng per mL; mean +/- 1 SD) with values significantly higher than controls (P <.0001) or patients either in steady state or VOC (P <. 01). NO metabolites were concomitantly decreased during ACS (9.2 +/- 1.5 nmol/mL) with values lower than controls (22.2 +/- 5.5), patients during steady state (21.4 +/- 5.5), or VOC (14.2 +/- 1.2) (P <.0001). Additionally, the ratio of soluble VCAM-1 to NO metabolites during ACS (132.9 +/- 46.5) was significantly higher when compared with controls (P <.0001) or patients either in steady state or VOC (P <.0001). Although hypoxia enhanced in vitro sickle erythrocyte-pulmonary microvessel adhesion, NO donors inhibited this process with concomitant inhibition of VCAM-1. We suggest that in ACS there is pathologic over expression of endothelial VCAM-1. Our investigations also provide a rationale for the therapeutic use in ACS of cytoprotective modulators including NO and dexamethasone, which potentially exert their efficacy by an inhibitory effect on VCAM-1 and concomitant inhibition of sickle erythrocyte-endothelial adhesion.


    • 1 May 1995
      • Vol. 125  (5) , 608-17

    Arachidonic acid metabolites are involved in mediating red blood cell adherence to endothelium.

    by B N Setty, C D Dampier, M J Stuart

    As an initial investigation into the possible role of endothelial cell (EC) lipoxygenase and cyclooxygenase metabolites in the adherence of red blood cells (RBCs) to ECs, we evaluated the effect of nordihydroguaiaretic acid, (NDGA; 10 mumols/L, BW755c (30 mumols/L), aspirin (100 mumols/L), and indomethacin (10 mumols/L) on RBC-EC adherence using a static incubation system and 51Cr-labeled RBCs. NDGA and 3-amino-L-[3'-(trifluoromethyl)phenyl]-2-pyrazoline inhibitors of both the lipoxygenase and cyclooxygenase pathways, significantly decreased basal adhesion of RBCs to fetal bovine aortic ECs, whereas aspirin and indomethacin, selective inhibitors of the cyclooxygenase pathway, stimulated the adherence process. The inhibitor effect appeared to be mediated via an effect on EC functions, since preincubation of ECs with NDGA, in contrast to RBC-NDGA preincubation, inhibited the adherence process. Because bovine aortic ECs generate mainly prostacyclin and 15-HETE from arachidonic acid (AA) via the cyclooxygenase and the lipoxygenase pathways respectively, the role of these products (100 pmol/L to 1 mumol/L) on the adhesive process was further assessed. 15-HETE potentiated basal adhesion of RBCs to bovine aortic ECs in a concentration-dependent manner, with maximal responses of approximately 50% to 150% over baseline noted at concentrations between 1 and 100 nmol/L 12-HETE, a structural isomer of 15-HETE and the major platelet lipoxygenase product, also stimulated RBC adherence. In contrast, prostacyclin (assessed using carbacyclin, a stable synthetic analog of prostacyclin with similar biologic properties) had no significant effect on this process. In further studies, we demonstrated that the 12-HETE-induced adherence of sickle RBCs was mediated via an up-regulation of the vitronectin receptor on bovine aortic endothelium. Because microvascular capillary endothelium is the surface most likely to encounter erythrocytes in vivo, we extended our studies to human retinal capillary ECs to assess the involvement of eicosanoids in sickle RBC-microvessel adhesion. As with bovine aortic ECs, aspirin stimulated and NDGA decreased the adherence of sickle RBCs to human retinal capillary endothelium. These microvascular ECs generated prostacyclin, HHT, 15-HETE, and 15-HPETE from endogenous AA. Although carbacyclin and HHT had no effect on the adherence process, both 15-HETE and 15-HPETE (10 pmol/L to 100 nmol/L) stimulated RBC adhesion to capillary endothelium. Our studies document a role for the lipoxygenase metabolites in modulating basal adhesion of RBCs to both macrovascular and microvascular endothelium; the major cyclooxygenase metabolites appear to play no role in this process.


    • 1 December 1992
      • Vol. 80  (11) , 2765-73

    15-Hydroxyeicosatetraenoic acid-mediated potentiation of thrombin-induced platelet functions occurs via enhanced production of phosphoinositide-derived second messengers--sn-1,2-diacylglycerol and inositol-1,4,5-trisphosphate.

    by B N Setty, M H Werner, Y A Hannun, M J Stuart

    We investigated whether biologically relevant concentrations of the mono-hydroxyeicosatetraenoic acids (mono-HETEs) modulate platelet functions. We report that 15-HETE, an eicosanoid produced by endothelial cells, granulocytes, and lymphocytes, potentiated platelet aggregation, nucleotide release, and elevation in intracellular calcium levels induced by a threshold concentration of thrombin (0.025 U/mL). Significant potentiation effects on these responses were observed at concentrations between 1 and 100 nmol/L. 15-HETE at these concentrations enhanced thrombin-induced platelet aggregation by 32% to 57%, nucleotide release by 40% to 65%, and elevation of intracellular calcium by 31% to 52% (P < .05 to .01). Both 12-HETE and 5-HETE, the structural isomers of 15-HETE, also potentiated thrombin-induced platelet aggregation and nucleotide release. While 12-HETE showed a small but significant effect at 100 pmol/L, 5-HETE had effects similar to those of 15-HETE at micromolar concentrations. To understand the mechanism of the HETE modulation of platelet functions, we studied the effect of 10 and 100 nmol/L 15-HETE on the production of sn-1,2-diacylglycerol (DAG) and inositol-1,4,5-trisphosphate (1,4,5-IP3). 15-HETE enhanced thrombin-induced production of DAG and 1,4,5-IP3 in a time- and concentration-dependent manner. 15-HETE also potentiated agonist-induced phosphorylation of the 47-Kd platelet protein. These studies demonstrate an important modulatory role for 15-HETE on platelet functions. Since this eicosanoid is elevated in pathologic states associated with platelet hyperfunction, including diabetes mellitus and atherosclerosis, an elucidation of its mechanism(s) of action appears relevant to our understanding of the genesis of atherothrombotic vascular disease.


  • THE MITOGENIC EFFECT OF 15-HETE ON ENDOTHELIAL CELLS IS MEDIATED VIA DIGLYCERIDE KINASE INHIBITION

    by B N Y Setty, M J Stuart

    We have previously demonstrated that 15-HETE, a mitogen for fetal bovine aortic endothelial cells (FBAECs), caused an accumulation of diglyceride (DG). Stimulation of DNA synthesis by 0AG (a synthetic DG analog) suggested that this mitogenic effect was mediated via elevation of cellular DG levels. In the present study we have delineated the mechanism by which 15-HETE causes DG accumulation by evaluating the effects of 15-HETE on the phosphati-dylinositol (PI) cycle. In [3H]inositol labeled cells, 15-HETE caused a decrease in PI content under both basal conditions (27%) and following A23187 stimulation (23%). The accumulation of DG and the decrease in PI suggested activation of phosphilipase C. However, no effect of 15-HETE was found on endothelial cell phos-pholipase C. A modulatory effect of 15-HETE on PI resynthesis was next evaluated using [3H] inositol. In 5 experiments, 15-HETE (30μM) inhibited the synthesis of PI in both unstimulated (51+15%, 1SD, P<0.001) and A23187 stimulated cells (80±19%, P<0.001). DG accumulation and inhibition of PI synthesis suggested a 15-HETE effect on the conversion of DG to phosphatidic acid (PA) via DG kinase. Using endothelial cell membranes as a source of this enzyme, formation of PA was nonlinear with time, suggesting an interference by PA phosphatase on PA formation. Human red cell membranes were therefore used in lieu of FBAECs as a source of DG kinase. In this system, production of PA was inhibited by 15-HETE in a concentration-dependent manner (IC50 of 22μM). This is the first report of the presence of a DG kinase inhibitor of biological origin. Our studies also delineate the mechanism by which 15-HETE exerts its mitogenic effect on endothelial cells.

  • 13-HYDROXY-9,11-OCTADECADIENOIC ACID (13-HOD) INCREASES PROSTACYCLIN PRODUCTION IN ENDOTHELIAL CELLS

    by B N Y Setty, M Berger, M J Stuart

    Recently, endothelial cells (ECs) have been shown to generate a potent vascular chemorepellant factor. This metabolite, 13-HOD is reported to be the major lipoxygenase product produced in microgram amounts in ECs (JBC 260:16056, 1985). We have studied the effect of 13-HOD on EC arachidonic acid (AA) metabolism, and report modulation of both AA release and conversion to prostacyclin. Using fetal bovine aortic ECs, 13-HOD stimulated prostacyclin production (RIA for 6KPGF1α ) by 40±13% (1SE), and 51±09% at 10 and 30μM (P1α by 31 to 51% between 5 and 120 min. (P14C]AA labeled cells, this compound modulated both AA release and its subsequent conversion. In 5 paired experiments, 13-HOD (30μM) enhanced the release of AA from membrane phospholipids (9065±0553 cpm/well in controls vs 10738±1725 in 13-HOD treated cells; PC0.01). Analysis of cellular phospholipids revealed a significant decrease in [14C]phosphatidylethanolamine (62312±3963 cpm/well in controls vs 56959±4104 in 13-HOD treated cells; P14C]prostacyclin was stimulated by 56±16% (P<0.01 ), while total cyclooxygenase metabolites increased by 28±8% (P<0.01), suggesting effects on both cyclooxygenase and prostacyclin synthetase. 13-HOD, the major vascular product of linoleic acid enhances both AA release and metabolism, thus demonstrating an intimate hemostatic interaction between the metabolic products of these two polyunsaturated fatty acids in endothelial cells.

  • PLATELET 12-HYDROXY-5,8,10-HEPTADECATRIENOIC ACID (HHT) STIMULATES PROSTACYCLIN PRODUCTION BY ENDOTHELIAL CELLS

    by M J Stuart, P D Sadowitz, B N Y Setty

    Although HHT accounts for approximately one third of the ara-chidonic acid (AA) metabolites produced by stimulated platelets, no well defined function has been attributed to this platelet product. We report that HHT stimulates prostacyclin production by endothelial cells, and have identified the mechanism for this effect. In human umbilical venous endothelial cells HHT (0.5 and 1pM) stimulated prostacyclin (RIA for 6KPGF1α) by 32±10% (1 SE) and 42±13% (P14C] AA metabolism in fetal bovine aortic endothelial cells (FBAECs) was studied. 6KPGF1α was stimulated by 25±9% and 30±6% at HHT cones, of 0.5 and 1μM (P14c] AA revealed that HHT (1μM) did not affect the ionophore stimulated release of AA from FBAEC membrane lipids (29521±11837 cpm/well control vs 32458+8811 in HHT treated cells, mean ±1SD) kinetic analyses revealed that HHT affected vascular cyclooxygenase. HHT (1μM) increased Vmax in test microsomes (706±21 pmol/mg/min) when compared to controls (529±20; P6 platelets control vs 2.28±1.62 in HHT treated platelets). In platelets prelabelled with [ 1-14c] AA, HHT (1μM) also had no effect on AA release post thrombin stimulation (5794_423 cpm per 108 platelets control vs. 6135±612 for paired HHT treated cells). Conversion to cyclooxygenase metabolites was also not enhanced (2605±265 vs 2806±332 for test platelets). HHT thus stimulates vascular prostacyclin without a concomitant effect on platelet AA metabolism. Our findings may explain the discrepancies relative to prostacyclin production in atherosclerosis and diabetes. In these disorders while ex vivo production of prostacyclin by vascular tissue is decreased, in vivo production is elevated. HHT may also be an important local modulator of platelet plug formation and could play a protective antithrombotic role by its hitherto unrecognized effect on vascular prostacyclin.